This is a renewal application of a training program at Icahn School of Medicine at Mount Sinai that is currently in its 17th year. In previous project periods, we have developed an innovative program in pharmacological sciences that has helped to establish Mount Sinai as one of the leaders in the nascent field of systems pharmacology. We were early advocates of introducing quantitative and computational training for all PhD candidates in biomedical sciences, and this remains the cornerstone principle of our curriculum. In coursework, students apply quantitative/computational approaches through problem solving and active learning exercises, and fundamental biological concepts underlying drug discovery and drug action are communicated within a disease context that promotes engagement. In addition to the rigorous and innovative curriculum, trainees in our program benefit from activities that enhance the research experience, including journal clubs, Works-in- Progress seminars, an annual retreat focused on career development, and an annual systems pharmacology symposium that provides networking opportunities. The coming project period will build on these successes and introduce new initiatives including flipped classrooms to maximize trainee flexibility, a new course that will be co-taught by pharmaceutical industry scientists, and formal training for all program mentors. For dissertation research, trainees can be mentored by any of 42 well-funded investigators with expertise in approaches in varied areas of pharmacology such as structure-based drug design, mathematical modeling of pathophysiology and drug action, and bioengineering. Students address cutting edge issues that must be solved to develop safe and effective therapeutics in disease areas such as cancer, cardiovascular disease, neurological disorders, diabetes, and kidney and liver disease. This structure has proven highly effective at producing successful young scientists. Trainees who have completed the program during the past 10 years have finished their PhDs in an average of 5.1 years and have typically produced nearly 5 total publications (average 4.88) and over 2 first author publications (average 2.2) resulting from their time in training at Mount Sinai. Program alumni have gone on to successful careers that collectively address many aspects of pharmacological sciences, both in academia and in the pharmaceutical industry.
We aim to continue to innovate and develop trainees who will become tomorrow?s leaders in pharmacology and address the urgent need for new approaches in drug development.

Public Health Relevance

The Integrated Training in Pharmacological Sciences program at Mount Sinai aims to train the next generation of leaders in drug development. Predoctoral students complete rigorous, quantitative coursework and are mentored in dissertation research by faculty who are leaders in their fields. Trainees who complete the program are poised for success in fields such as systems pharmacology and structure-based drug design.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
2T32GM062754-19
Application #
9645455
Study Section
NIGMS Initial Review Group (TWD)
Program Officer
Koduri, Sailaja
Project Start
2001-07-05
Project End
2024-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
19
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Pharmacology
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ackeifi, Courtney A; Swartz, Ethan A; Wang, Peng (2018) Cell-Based Methods to Identify Inducers of Human Pancreatic Beta-Cell Proliferation. Methods Mol Biol 1787:87-100
Ung, Peter Man-Un; Rahman, Rayees; Schlessinger, Avner (2018) Redefining the Protein Kinase Conformational Space with Machine Learning. Cell Chem Biol 25:916-924.e2
Barrette, Anne Marie; Bouhaddou, Mehdi; Birtwistle, Marc R (2018) Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. ACS Chem Neurosci 9:118-129
Long, Rose G; Rotman, Stijn G; Hom, Warren W et al. (2018) In vitro and biomechanical screening of polyethylene glycol and poly(trimethylene carbonate) block copolymers for annulus fibrosus repair. J Tissue Eng Regen Med 12:e727-e736
Rifkin, Robert A; Huyghe, Deborah; Li, Xiaofan et al. (2018) GIRK currents in VTA dopamine neurons control the sensitivity of mice to cocaine-induced locomotor sensitization. Proc Natl Acad Sci U S A 115:E9479-E9488
Koch, Rick J; Barrette, Anne Marie; Stern, Alan D et al. (2018) Validating Antibodies for Quantitative Western Blot Measurements with Microwestern Array. Sci Rep 8:11329
Varshneya, Meera; Devenyi, Ryan A; Sobie, Eric A (2018) Slow Delayed Rectifier Current Protects Ventricular Myocytes From Arrhythmic Dynamics Across Multiple Species. Circ Arrhythm Electrophysiol 11:e006558
Xiong, Yuguang; Soumillon, Magali; Wu, Jie et al. (2017) A Comparison of mRNA Sequencing with Random Primed and 3'-Directed Libraries. Sci Rep 7:14626
Gillespie, Stephanie R; Tedesco, Liana J; Wang, Lingyan et al. (2017) The deubiquitylase USP10 regulates integrin ?1 and ?5 and fibrotic wound healing. J Cell Sci 130:3481-3495
Cheung, Kalung; Lu, Geming; Sharma, Rajal et al. (2017) BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice. Proc Natl Acad Sci U S A 114:2952-2957

Showing the most recent 10 out of 113 publications